NCIt definition : A human bispecific antibody targeting both epidermal growth factor receptor EGFR and
hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity.
Upon administration, amivantamab simultaneously targets and binds to wild-type or
certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing
receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated
signaling pathways. In addition, binding results in receptor degradation, which further
inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent
cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor
cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor
cell types, play key roles in tumor cell proliferation.;
UNII : 0JSR7Z0NB6;
CAS number : 2171511-58-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2171511-58-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;